Product image of Olectan (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olectan

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olectan (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olectan, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, often when monotherapy does not provide adequate blood pressure control.

GNH India supplies Olectan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olectan is used in the management of high blood pressure, a key component of cardiovascular disease prevention.

  • Hypertension: lowers systolic and diastolic blood pressure to reduce risk of stroke and heart attack.
  • Hypertension in patients who require dual therapy: provides combined angiotensin‑II receptor blockade and calcium‑channel blockade.
  • Hypertension with concomitant edema risk: amlodipine’s vasodilatory effect mitigates fluid retention associated with ARBs.

How It Works

  • Olmesartan medoxomil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone‑driven sodium retention. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination yields additive blood‑pressure‑lowering effects through complementary inhibition of the renin‑angiotensin system and direct vascular smooth‑muscle relaxation.

Side Effects

Adverse reactions may occur with any antihypertensive combination therapy.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness or light‑headedness, especially after the first dose.
  • Flushing: transient warmth and redness.
  • Fatigue: general tiredness.
  • Nausea: occasional stomach upset.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of lips, tongue or airway.
  • Severe hypotension: symptomatic low blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.
  • Acute kidney injury: sudden decline in renal function.
  • Hyperkalemia: elevated potassium levels.
  • Myocardial infarction: rare but reported in susceptible patients.

Precautions & Warnings

Before initiating Olectan, clinicians should assess patient history and comorbid conditions.

  • Renal impairment: adjust dose or monitor renal function regularly.
  • Hepatic disease: use with caution; monitor liver enzymes.
  • Electrolyte disturbances: check potassium and sodium levels.
  • Pregnancy: contraindicated in the second and third trimesters; avoid use.
  • Elderly patients: start at lower dose and monitor for orthostatic hypotension.
  • Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Olectan may interact with several drug classes; careful review of the patient’s medication list is essential.

Major Interactions (Avoid)

  • Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure.
  • Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): excess hypotension.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
  • Diuretics: additive blood‑pressure lowering, monitor electrolytes.
  • Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.

Frequently Asked Questions

Olectan is a fixed‑dose combination of olmesartan medoxomil and amlodipine that is prescribed to lower high blood pressure in adults, especially when a single‑agent therapy does not achieve target blood‑pressure levels.

Olmesartan medoxomil is an angiotensin‑II receptor blocker; it selectively blocks AT‑1 receptors, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone release, which helps to relax blood vessels and reduce fluid retention.

The dose of Olectan is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function and other medications. The prescriber determines the appropriate strength and dosing schedule.

Olmesartan is contraindicated in the second and third trimesters of pregnancy because of the risk of fetal toxicity. Amlodipine is generally avoided during pregnancy unless clearly needed. Breastfeeding mothers should consult their physician before using Olectan.

To order Olectan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olectan combines an ARB (olmesartan) with a calcium‑channel blocker (amlodipine), offering complementary mechanisms that often achieve better blood‑pressure control than either component alone. Compared with monotherapy, the combination can reduce the need for dose escalation and may lower the incidence of edema associated with amlodipine alone.

Store Olectan tablets below 25 °C in the original packaging, protecting them from moisture, heat and direct sunlight to maintain potency throughout the shelf‑life.

Olectan is taken orally, usually once daily, with or without food. Patients should follow the prescribing physician’s instructions regarding timing and whether to swallow the tablet whole.

Serious risks include angio‑edema, severe hypotension, acute kidney injury, hepatic dysfunction and hyper‑kalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, fainting, or sudden changes in urine output.

Olectan is contraindicated in patients with known hypersensitivity to olmesartan, amlodipine or any excipients, in pregnant women beyond the first trimester, and in individuals receiving concurrent therapy with other ARBs, ACE inhibitors or direct renin inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT